FY2025 EPS Estimates for MeiraGTx Lowered by Chardan Capital

MeiraGTx Holdings plc (NASDAQ:MGTX) – Chardan Capital dropped their FY2025 earnings per share (EPS) estimates for shares of MeiraGTx in a note issued to investors on Wednesday, May 14th. Chardan Capital analyst D. Gataulin now expects that the company will post earnings per share of ($1.05) for the year, down from their prior forecast of $0.25. Chardan Capital currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for MeiraGTx’s current full-year earnings is ($1.48) per share. Chardan Capital also issued estimates for MeiraGTx’s FY2026 earnings at ($0.95) EPS.

MeiraGTx (NASDAQ:MGTX) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.13). MeiraGTx had a negative net margin of 633.05% and a negative return on equity of 146.38%. The firm had revenue of $1.93 million during the quarter, compared to analyst estimates of $4.44 million.

Separately, Royal Bank of Canada raised their target price on MeiraGTx from $11.00 to $13.00 and gave the company an “outperform” rating in a report on Monday, March 17th.

MeiraGTx Stock Up 6.8%

Shares of MGTX opened at $5.50 on Monday. MeiraGTx has a 52-week low of $3.85 and a 52-week high of $8.75. The company has a market capitalization of $442.01 million, a PE ratio of -4.55, a price-to-earnings-growth ratio of 0.37 and a beta of 1.30. The stock has a fifty day simple moving average of $6.21 and a two-hundred day simple moving average of $6.34. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.86.

Insider Transactions at MeiraGTx

In related news, CFO Richard Giroux sold 24,000 shares of the stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $6.00, for a total transaction of $144,000.00. Following the transaction, the chief financial officer now directly owns 882,494 shares in the company, valued at approximately $5,294,964. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Alexandria Forbes sold 47,500 shares of the stock in a transaction dated Tuesday, April 8th. The stock was sold at an average price of $5.34, for a total value of $253,650.00. Following the transaction, the chief executive officer now owns 1,408,983 shares in the company, valued at $7,523,969.22. This trade represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.50% of the company’s stock.

Hedge Funds Weigh In On MeiraGTx

A number of large investors have recently modified their holdings of MGTX. AQR Capital Management LLC acquired a new position in shares of MeiraGTx in the 1st quarter worth approximately $557,000. 683 Capital Management LLC grew its holdings in shares of MeiraGTx by 6.6% in the 1st quarter. 683 Capital Management LLC now owns 2,575,000 shares of the company’s stock worth $17,458,000 after acquiring an additional 160,000 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in shares of MeiraGTx by 11.9% during the first quarter. Adage Capital Partners GP L.L.C. now owns 5,634,578 shares of the company’s stock valued at $38,202,000 after buying an additional 600,000 shares in the last quarter. Long Focus Capital Management LLC grew its stake in MeiraGTx by 31.6% in the first quarter. Long Focus Capital Management LLC now owns 249,745 shares of the company’s stock valued at $1,693,000 after purchasing an additional 60,000 shares in the last quarter. Finally, Trexquant Investment LP grew its stake in MeiraGTx by 12.6% in the first quarter. Trexquant Investment LP now owns 44,318 shares of the company’s stock valued at $300,000 after purchasing an additional 4,970 shares in the last quarter. 67.48% of the stock is currently owned by hedge funds and other institutional investors.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.